Breaking News Instant updates and real-time market news.

ZYNE

Zynerba

$19.43

0.49 (2.59%)

, GWPH

GW Pharmaceuticals

$106.15

-0.52 (-0.49%)

14:29
07/17/17
07/17
14:29
07/17/17
14:29

Before the Move: Watch Zynerba ahead of trial data

With Zynerba Pharmaceuticals (ZYNE) expected to release data from a Phase 2 trial over the next several weeks, Jefferies analyst Biren Amin recently argued that a positive update could lead the shares north of $65-$75. However, a lack of treatment effect could drop the stock to $4-$5. CANNABIDIOL GEL: Over the coming weeks, Zynerba is expected to announce data from its ZYN002 cannabidiol, or CBD, gel Phase 2 STAR 1 trial in adult epilepsy patients with refractory focal seizures. ZYN002 is a synthetic CBD formulated as a permeation-enhanced gel for transdermal delivery. BINARY EVENT: In a research note to investors, Jefferies' Amin pointed out that the STAR-1 trial represents a "critical catalyst" for Zynerba as it provides the first proof of concept for transdermally delivered CBD. Given investors naturally compare the program to GW Pharma's (GWPH) Epidiolex, and oral CBD, the analyst believes a better comparison would be to therapies tested in patients with partial-onset seizures who are uncontrolled on their current therapy. Additionally, Amin noted that while the study is designed for a 20% treatment effect over a placebo, an effect greater than 15% could be considered clinically relevant. A key question that remains unanswerable is the extent of activity observed with ZYN002 given this is the first study evaluating efficacy in epilepsy patients, he contended. Amin told investors that positive data could lead to shares north of $65-$75, but a lack of treatment effect could drop shares to $4-$5. The analyst assumes ZYN002 is successfully developed and launched for refractory epilepsy in 2019. Amin reiterated a Buy rating and a $32 price target on the shares. PRICE ACTION: In Monday afternoon trading, shares of Zynerba have dropped 3% to $18.82. Over the last month the stock is up 10%, but over the last three months it has declined nearly 24%. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.

ZYNE

Zynerba

$19.43

0.49 (2.59%)

GWPH

GW Pharmaceuticals

$106.15

-0.52 (-0.49%)

ZYNE Zynerba
$19.43

0.49 (2.59%)

06/26/17
OPCO
06/26/17
NO CHANGE
Target $29
OPCO
Outperform
Zynerba risk/reward favorable after pullback, says Oppenheimer
Oppenheimer analyst Derek Archila views the risk/reward for shares of Zynerba Pharmaceuticals as favorable with the shares down 30% since April. The company has "multiple shots on goal" to create value, Archila tells investors in a research note. The analyst notes that Zynerba has three Phase 2 read-outs for ZYN002 in the July-September time frame, for refractory epilepsy, knee osteoarthritis and Fragile X syndrome. The analyst has an Outperform rating on the shares with a $29 price target.
06/12/17
MAXM
06/12/17
NO CHANGE
Target $32
MAXM
Buy
Zynerba an 'excellent value' compared to GW Pharmaceuticals, says Maxim
Maxim analyst Gabrielle Zhou said she views Zynerba's (ZYNE) product candidates as "de-risked" alternatives to GW Pharmaceuticals' (GWPH) and calls the stock an "excellent value play" compared to GW, citing the facts that ZYN002 has a better safety and bioavailability profile than GW Pharma's Epidiolex. ZYN002 is also synthetic, not plant based, which could lead to higher margins and better quality control, Zhou tells investors. She keeps a Buy rating and $32 price target on Zynerba shares, adding that 2017 could be "transformational" for the company.
03/31/17
OPCO
03/31/17
NO CHANGE
Target $29
OPCO
Outperform
Oppenheimer remains positive on Zynerba ahead of near-term catalysts
Oppenheimer analyst Derek Archila notes that Zynerba reported Q4 financial results and provided updates on its three ongoing Phase 2 studies for ZYN002 in adult epilepsy, knee osteoarthritis, and Fragile X syndrome, and remains on track to report data for its Phase 2 trials in adult epilepsy and knee osteoarthritis in July/August. Ahead of these near-term catalysts, the analyst remains positive on the shares, though he reminds investors Zynerba is a high-risk/high-reward potential investment. Archila reiterates an Outperform rating and $29 price target on the shares.
03/28/17
HCWC
03/28/17
NO CHANGE
Target $30
HCWC
Buy
Zynerba price target raised to $30 from $22 at H.C. Wainwright
H.C. Wainwright analyst Corey Davis raised his price target for Zynerba Pharmaceuticals to $30 after the company specified yesterday that both its Phase 2 studies with ZYN002, in epilepsy and osteoarthritis pain, will read out in July or August, with epilepsy coming first. The analyst thinks the gel has a "high chance of working." Medical marijuana has utility in a number of different settings and regulators would prefer to have the active compound isolated, regulated, and delivered in a consistent manner, Davis tells investors in a research note. The analyst keeps a Buy rating on Zynerba following the company's Q4 results.
GWPH GW Pharmaceuticals
$106.15

-0.52 (-0.49%)

06/09/17
MAXM
06/09/17
NO CHANGE
MAXM
Buy
GW Pharmaceuticals orphan designation an incremental positive, says Maxim
Maxim analyst Gabrielle Zhou noted that GW Pharmaceuticals received FDA orphan designation for cannabidivarin for treatment of Fragile X syndrome, calling the news an incremental positive. The analyst, who notes that the next investor focus is the phase 2 data expected to be announced mid-2017 for GWP42006 in adult epilepsy, keeps a Buy rating on GW shares.
05/25/17
LEER
05/25/17
NO CHANGE
LEER
Outperform
NEJM validation for Epidiolex, but controversy remains, says Leerink
Leerink analyst Paul Matteis believes publication of the first Dravet study in the New England Journal of Medicine offers "further validation of the robustness" of the positive phase III trial for GW Pharmaceuticals' Epidiolex. No new safety issues were disclosed and statistical sensitivity analyses corroborated the positive primary efficacy analysis, Matteis tells investors in a research note. Not included in the publication, however, is further color on the clobazam drug-drug interaction, which continues to remain a subject of investor controversy and interest heading into the mid-2017 new drug application filing, Matteis writes. He reiterates an Outperform rating on GW shares.
04/21/17
MAXM
04/21/17
INITIATION
Target $135
MAXM
Buy
GW Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Lauren Chung initiated GW Pharmaceuticals with a Buy rating and $135 price target, calling the company the "market leader" in cannabis therapeutics with a first-mover advantage in epilepsy.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$29.18

-0.46 (-1.55%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Aclaris Therapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Week of 7/28 Baker-Hughes…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

JAGX

Jaguar Animal Health

$0.66

-0.0175 (-2.58%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Jaguar Animal Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

CALM

Cal-Maine Foods

$38.05

0.55 (1.47%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Cal-Maine Foods participates in a conference call with Stephens »

Stephens hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

, IBM

IBM

$145.07

-0.29 (-0.20%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
RSA Security to hold a conference »

RSA Security Conference…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

IBM

IBM

$145.07

-0.29 (-0.20%)

CTL

CenturyLink

$23.60

0.74 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

03:35
07/28/17
07/28
03:35
07/28/17
03:35
General news
FX Action: USD-CAD steady after posting its biggest one-day gain »

FX Action: USD-CAD steady…

01:40
07/28/17
07/28
01:40
07/28/17
01:40
General news
FX Update: The Swiss franc tumbled for a four straight session »

FX Update: The Swiss…

TOO

Teekay Offshore Partners

$2.55

-0.03 (-1.16%)

20:27
07/27/17
07/27
20:27
07/27/17
20:27
Downgrade
Teekay Offshore Partners rating change at Raymond James »

Teekay Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Downgrade
QEP Resources rating change at JPMorgan »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

RDFN

Redfin

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Syndicate
Redfin 9.231M share IPO priced at $15.00 »

The deal range is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 28

    Jul

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

, CVX

Chevron

$106.11

0.99 (0.94%)

20:25
07/27/17
07/27
20:25
07/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

CVX

Chevron

$106.11

0.99 (0.94%)

MRK

Merck

$63.69

1.89 (3.06%)

ABBV

AbbVie

$71.73

-0.86 (-1.18%)

AAL

American Airlines

$50.00

-1.01 (-1.98%)

COL

Rockwell Collins

$109.02

-0.53 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 07

    Aug

  • 28

    Aug

  • 22

    Sep

TTPH

Tetraphase

$6.96

-0.92 (-11.68%)

20:22
07/27/17
07/27
20:22
07/27/17
20:22
Syndicate
Tetraphase 10M share Secondary priced at $6.50 »

Piper Jaffray, BMO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

BVN

Buenaventura

$12.45

0.1 (0.81%)

19:26
07/27/17
07/27
19:26
07/27/17
19:26
Earnings
Buenaventura reports Q2 EPS (2c), may not compare to consensus 26c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:02
07/27/17
07/27
19:02
07/27/17
19:02
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:01
07/27/17
07/27
19:01
07/27/17
19:01
Earnings
Basic Energy reports Q2 adjusted EPS (57c), consensus (55c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

GE

General Electric

$25.79

0.2 (0.78%)

18:55
07/27/17
07/27
18:55
07/27/17
18:55
Periodicals
Breaking Periodicals news story on General Electric »

Uber CEO shortlists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AIV

Aimco

$44.01

0.13 (0.30%)

18:53
07/27/17
07/27
18:53
07/27/17
18:53
Earnings
Aimco reports Q2 AFFO 51c vs 50c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

NOV

National Oilwell

$33.71

0.37 (1.11%)

18:43
07/27/17
07/27
18:43
07/27/17
18:43
Earnings
National Oilwell reports Q2 adjusted EPS (14c), consensus (15c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 29

    Aug

AIG

AIG

$65.17

-0.02 (-0.03%)

, IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

18:39
07/27/17
07/27
18:39
07/27/17
18:39
Periodicals
Senators worried over whether Icahn is pushing regulators on AIG, Reuters says »

U.S. Democratic Senators…

AIG

AIG

$65.17

-0.02 (-0.03%)

IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

PRU

Prudential

$112.74

0.55 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 03

    Aug

  • 27

    Sep

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

18:24
07/27/17
07/27
18:24
07/27/17
18:24
Earnings
Heritage Commerce reports Q2 EPS 19c, consensus 19c »

Reports Q2 NII $24.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.